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treatment and monthly up until 3 months after finishing treatment. 
Treatment outcome at 3 and 6 months was retrieved in 131 patients. 
A two-tailed Fisher’s Exact test was used to compare binary data 
between both arms. A Mann-Whitney U test was performed to 
compare continuous data.  
Results: Data of 193 patients could be retrieved (experimental arm: 
n=96 , standard arm: n= 97). No significant differences between both 
arms were seen in social status, age, sex, tumor site, smoking and 
alcohol abuse, TNM stage, performance stage, total dose delivered, 
overall treatment time and pretreatment dysphagia. Dosimetrically, 
no significant difference was seen between both arms concerning 
PTVther coverage (for D95: 67.5 Gy vs 67.3 Gy; p=0.9). As expected the 
median D95 of the PTVelect was significantly lower in the experimental 
arm than in the standard arm (39.5 Gy vs 49.8 Gy; p<0.0001). Using 
this strategy we were able to significantly reduce the dose to 
swallowing structures (Table 1). There was no significant difference in 
acute mucositis, skin toxicity and weight loss between both groups. 
During treatment no difference was seen in severe dysphagia. Three 
months after radiotherapy however there was significantly less grade 
3+ dysphagia in the experimental arm compared to the standard arm 
(2% vs 11%; p=0.03) (Figure 1). At 6 months, no significant difference 
was seen in locoregional control between both arms (88% vs 92%; 
p=0.6). 
Conclusions: Using IMRT we were able to significantly reduce the dose 
to the elective nodal volumes and several organs at risk without 
compromising PTVther coverage. This resulted in a significant reduction 
of severe dysphagia 3 months after radiotherapy, without 
compromising locoregional control. Further follow-up is necessary to 
investigate whether these observations translate into a benefit on late 
treatment related dysphagia without affecting treatment outcome.  
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Purpose/Objective: To compare conventional fractionation 
radiotherapy (RT, Arm A), conventional fractionation RT with 
concurrent chemotherapy (CTRT, Arm B) and accelerated 
radiotherapy (ART, Arm C), in terms of survival and toxicity for loco-
regionally advanced, non-nasopharyngeal, Squamous Cell Carcinoma 
Head and Neck (HNSCC). 
Materials and Methods: Between April 2000 and October 2007, 179 
previously untreated, non metastatic, Stage III and IV HNSCC were 
randomised. There were 53, 64 and 62 patients in Arm A, B and C 
respectively. In arms A and B, all patients received conventional 
fractionation RT to a total dose of 66-70Gy in 6-7 weeks, five fractions 
per week. In Arm B, concurrent CT regimen consisted of Cisplatin 30 
mg/m2/week. In Arm C, the total dose of radiotherapy was same, 6 
fractions were administered per week, with concomitant boost being 
given on Saturday. Analysis was on an intention-to-treat basis. 
Results: The median age of cohort was 49 years. The age, sex, 
primary sites, stage of disease were equally distributed in all three 
arms. Oropharynx was the most common primary site in all the three 
arms. The median treatment duration was 49, 51 and 40 days in 3 
arms respectively. In arm B, the median number of chemotherapy 
cycles was 6. The mean and median follow up was 37.7 and 23 months 
respectively (Inter-quartile range 10-59 months). There was a 
significant difference in the Disease-Free Survival (DFS) and Overall 
survival (OS) for CT-RT arm compared with the others. The Median 
DFS in Arm A was 16 months compared to 34 months in Arm B and 10 
months in Arm C (p=0.02). Median OS in Arm A was 32 months 
compared to 76 months in Arm B and 32 months in Arm C (p=0.05). In 
terms of acute toxicities patients of Arm A experienced fewer Grade 3 
or more oral mucositis compared to Arms B & C (11 versus 22 versus 
19 respectively). No incidence of G3 or more haematological toxicity 
was seen during the treatment in either of the arms. There was no 
difference in acute grade 3 skin toxicity or significant sequelae 
between the arms (14 versus 15 versus 10 respectively). In terms of 
late toxicities (RTOG Scale) G2-G3 xerostomia was similar in all the 
three arms (10 versus 14 versus 11 respectively). Similarly the late 
toxicity in terms of skin, mucosa and subcutaneous tissue was similar 
in the 3 arms. Salvage surgery was done in 19 patients (4 versus 6 
versus 9 respectively in Arms A, B & C). Thirteen patients developed 
second primary cancer (3 versus 5 versus 5 respectively in Arms A, B & 
C). 
Conclusions: Concurrent CTRT is associated with significant better OS 
and DFS as compared to RT alone (Conventional or Accelerated) 
without significant increase in late toxicities.  
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Purpose/Objective: To assess the role of domiciliary based 
humidification (HUM) on the natural history of mucositis during 
radiotherapy (RT) for head and neck cancer. To evaluate the impact 
of HUM on patient reported outcomes (PRO). 
Materials and Methods: In this phase III multi-site trial, patients with 
SCC of the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx 
receiving definitive or adjuvant RT ± chemotherapy were randomised 
to either institutional standard of care (control) or HUM using the 
Fisher and Paykel Healthcare MR880 humidifier. HUM commenced day 
1 of RT and continued until CTCAE version 3.0 mucositis clinical exam 
score (CMuc) was <1. Compliance was recorded electronically. HUM 
Compliance ratio (HCR) was calculated using the formula: total days 
compliance > 4 hours from RT start to CMuc < grade 1 / total days 
from RT start to CMuc <grade 1. HCR of > 0.33 was set as the cutoff 
for the per protocol population analysis (PPA). CMuc was assessed 
weekly until week 12 or resolution of CMuc score < 1. The primary 
endpoint was the area under the curve (AUC) of CMuc grade >1. A 
credentialing programme promoted CMuc scoring consistency among 
investigators. The secondary endpoint CTCAE v 3.0 mucositis 
functional score (FSMuc) was analysed with similar methodology. PRO 
assessments included McMaster University Head and Neck 
Questionnaire (HRNQ) at baseline, 4, 7,12 and 20 weeks. Symptom 
cluster questions within HRNQ associated with mucositis analysed in 
addition to the normal HNRQ domains included severe cluster 
(difficulty tasting food, clearing secretions, swallowing or chewing) 
and moderate cluster (low energy, fatigue, dryness mouth, reduced 
appetite, pain mouth, pain throat, difficulty sleeping). The primary 
PRO comparison was the difference in means between the 2 arms at 
each timepoint. 
Results: 210 patients were randomised (control 105; HUM 105). There 
was no difference in AUC CMuc means for the intention to treat 
population (ITT): control 9.0 (95% CI; 8.1 – 10.0); HUM 8.9 (95% CI; 8.0 
–9.8); p 0.97. When patients with HCR < 0.33 were excluded for the 
PPA (60HUM patients; 58%), there was again no difference: control 9.0 
(8.1 – 10.0) HUM 7.8 (6.3 – 9.2) p 0.25. There was no difference in AUC 
FSMuc for ITT: control 9.6 (8.7 – 10.4) HUM 8.8 (8.0 – 9.5); p 0.22, but 
a significant difference for PPA: control 9.6 (8.7 – 10.4) HUM 7.7 (6.7 – 
8.7); p 0.009. For HNRQ ITT analysis, there was no difference in 
outcomes at any timepoint. The HNRQ PPA showed few significant 
differences but estimates were in the direction that favoured HUM 
with less symptom severity. 
Conclusions: There was no difference in the primary endpoint of AUC 
CMuc with HUM. There is a trend in the HNRQ PPA suggestive of 
efficacy with HUM which is reflected in the AUC FSMuc PPA as well but 
the major difficulties in achieving consistent patient compliance 
suggests this is not an effective therapy for mucositis in its current 
format.  
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Treatment of patients with oligo-metastasic disease has moved into 
focus since it has been shown that limited disease volume and sites 
contribute favorably to outcome. This is also relevant in metastastic 
lesions to the brain. However, due to the dose-response relationship 
